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Introduction 
GBS neonatal infections 
Intrapartum screening 
 
GBS neonatal infections 
• In Belgium: 110 à 120000 birth/year 
 
• EOD and LOD incidence < 1 ‰ 
 
• No mandatory statement 
• Estimation: around  50 EOD/year 
     50 LOD/year 
Prevention 
IAP Immunoprophylaxie 
• First guidelines  
▫ 2002 USA 
▫ 2003 Belgique 
• Vagino-rectal universal 
screening at 35-37 weeks’ 
gestation 
▫ If positive result: 
pen/cephalo/clinda/vanco 
▫ If unknown result: 
 obstetrical risk factors 
• Effective on EOD 
 
• In development 
 
• Effective on EOD and LOD 
 
Prevention (2) 
Figure 1 : EOD and LOD incidence between 1990 and 2008 (Revised Guidelines from CDC, 2010)                                                                                             
ACOG = American College of Obstetricians and Gynecologists et AAP = American Acad-emy of Pediatrics. 
 
Detection of EOD risk =                    
GBS + at delivery 
Antenatal screening Intrapartum screening 
• VPP 60 à 87% 
• VPN 88 à 96% 
 
• False negative:  missed IAP 
• False positive: unnecessary 
IAP 
• Expected PPV and NPV >90% 
 
 
• Better targeted IAP 
 
 
• No susceptibility testing 
Required features for an intrapartum 
test (1) 
• High sensitivity and specificity 
• Full automation 
• Easy to perform and interpret by nurses 
• Time to result: maximum 1 hour 
• 24/24 hours et 7/7 days available 
 
Required features for an intrapartum 
test (2) 
• Awaited > 20 years 








→ Xpert GBS test proposed by the European Expert Group * 
 
Authors Revue Number of 
included 
patients 
Test Site S Sp PPV NPV 
Abdelazim IA 2013 Aust N Z Obstet 
Gynaecol 
445 Xpert GBS Lab 98.3% 99% 97.4% 99.4% 
Park JS et al. 2013 Ann Lab Med 175 Xpert GBS Lab 86.6% 95.6% 65% 98.7% 
Church DL et al. 2011 Diag Microbiol 
Infect Dis 
231 Xpert GBS Lab 100% 100% 100% 100% 
De Tejada BM et al. 2011 Clin Microbiol 
Infect 
695 Xpert GBS Obstetrics 
facility 
85% 96.6% 85.7% 96.3% 
Young BC et al. 2011 Am J Obstet 
ynecol 
559 Xpert GBS Lab 90.8% 97.6% 92.2% 97.1% 
El Helali N et al. 2009 Clin Infect Dis 968 Xpert GBS Lab 98.6% 99.6% 97.8% 99.7% 
* Intrapartum GBS screening and antibiotic prophylaxis : a European consensus conference. J Matern Fetal Neonatal 
Med 2014;27:1-17. 
Test Xpert GBS 
• Real Time PCR on GeneXpert system (Cepheid). 
▫ Amplification of a conserved region adjacent to 
the cfb gene of GBS 
• On vaginal or vagino/rectal swab 
• Fully automated 
• Easy handling 
• Result in 45 minutes 
 
Ongoing study in CHU Liège / UZ 
Antwerp: Aims 
1. To assess the practical and analytical aspects of 
the implementation of the PCR test Xpert GBS® 
in Belgium 
▫ Performed by midwives 
▫ For all women at onset of labor 
 
2. To evaluate the cost-effectiveness of the 
intrapartum screening strategy 
 
→ To consolidate the proposal of the European 
Expert Group 
Material and methods 
Population 
Specimen collection 
Test Xpert GBS 
Population 
• Prospective study in 2 Belgian hospitals: CHU 
Liège and UZ Antwerp 
 
• Sample size in CHU Liège: 500 
• ALL women at onset of labor included 
 
• Case-report form 
▫ Demographic and obstetric data 




Prenatal screening Intrapartum screening 
• vagino/rectal specimen 
collected at 35-37 weeks’ 
gestation 
 
• vaginal specimen using a 
double swab  




Test Xpert GBS 
a/Granada, b/StrepB Select, c,d/GS-CNA 
Test Xpert GBS: Procedure 
• Procedure performed by midwives 
• GeneXpert system installed at the Obstetrics facility  
Test Xpert GBS: Results 
Indeterminate 
status for GBS 
 
Negative for GBS 
Presence of GBS 
Test Xpert GBS: Results (2) 
• Algorithm proposed to clinicians:  
  
 Integration of the intrapartum Xpert result in 
addition to : 
▫ patient’s clinical data 








• Study period : 8/4 au 03/10/2014 (still ongoing) 
• 658 deliveries 
 
• Included patients : 486 Xpert® GBS tests 
performed (74%)  
▫ Inclusion rate lower among antenatally positive 
screened patients. 
Culture results 
• Colonization rate (35-37 weeks): 19.4% 
 
• Performances of the antenatal culture screening 
 
 
▫ intrapartum culture as gold standard 
 
Sensitivity Specificity PPV NPV 
67.3 % 94.2 % 68.8 % 93.8 % 
PCR results 
• Not yet available for presentation  
 
• Difficulties encountered: 
▫ Low inclusion rate 
▫ Wrong manipulations 
▫ Invalid results 
 
• Study still ongoing, with a revised protocol 
Discussion 
Intrapartum PCR: Inclusion rate 
• Lower than expected 
• Bias linked to low inclusion of antenatally 
positive detected women  
 
• 100% inclusion rate is utopian: 
▫ Delay before delivery too short, high workload 
▫ Technical problems, lack of involvement in the 
study. 
Intrapartum PCR: Handling 
• Test easy to perform « a priori » BUT… 
• Many difficulties encountered by midwives : 
▫ Sample preparation 
▫ Proper breaking into the cartridge 
▫ Loading in the instrument 
• Large team, high turn-over 
 
→ Continuous training required 
Conclusion (1) 
• Intrapartum screening:  
▫ Proven clinical value 
▫ Recommended by new European directives 
▫ Cost-effectiveness remains to be demonstrated in 
Belgium 
• Test Xpert GBS : 
▫ Sensible et specific 
▫ Fully automated 
▫ Fast result 
▫ Feasible in point-of-care, 24h/24 




Necessary supervision by the lab : 
• Careful training of operators 
• Verification of test performance before routine 
implementation 
• Daily technical supervision 
• Involvement of gynecologists: 
▫ ensure adequate inclusion rates 
▫ integrate the result of the rapid test in the care of 
the patient 
Conclusion (3) 
Is the Xpert® GBS test enough robust to be 
universally recommended as a POCT ?  
 
 
Desired developments at Cepheid : 
• Internal control checking for human cells 
• Simplifying the interface of the GeneXpert 
system 
Thank you ! 
